Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases

Nuclear Medicine Communications

Volumn 30, Issue 2, 2009, Pages 117-125

  D'Souza, Maria Mathew ^a,b   Sharma, Rajnish ^a   Mondal, Anupam ^a   Jaimini, Abhinav ^a   Tripathi, Madhavi ^a   Saw, Sanjiv Kumar ^a   Singh, Dinesh ^a   Mishra, Anil ^a   Tripathi, Rajendra Prasad ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b EC 285 Maya Enclave ^*  (India)

Author keywords

18F fluorodeoxy D glucose positron emission tomography computed tomography; Contrast enhanced computed tomography; Hepatic metastases; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; NONIONIC CONTRAST MEDIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LIVER METASTASIS; MALE; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOGRAPHY, ABDOMINAL; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 58549101162     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32831ec57b     Document Type: Article

References (33)

1. Kuker RA, Mesoloras G, Gulec SA. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol 2007; 4:17.
2. Bengmark S, Hafstrom L, Olsson A. The natural history of primary and secondary liver tumors. V. The prognosis for conventionally treated patients with liver metastases. Digestion 1972; 6:321-329.
3. Brant WE. Liver. In: Webb WR, Brant WE, Helms CA, editors. Fundamentals of body CT. 2nd ed. Philadelphia: WB Saunders; 1998. pp. 195-212.
4. Goslin R, Steele G Jr, Zamchek N, Mayer R, MacIntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982; 25:749-754.
5. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: Biologic perspective. Ann Surg 1989; 210:127-138.
6. Choi J. Imaging of hepatic metastases. Cancer Control 2006; 13:6-12.
7. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224:748-756.
8. Small R, Lubezky N, Ben-Haim M. Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J 2007; 9:742-747.
9. (18)F-FDG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007; 13:5025-5029.
10. Griffeth LK. Use of PET/CT scanning in cancer patients: technical and practical considerations. Proc (Baylor Univ Med Centre) 2005; 18: 321-330.
11. Arulampalam TH, Francis DL, Visvikis D,Taylor I, EII PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 2004; 30:286-291.
12. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21:517-522.
13. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438-450.
14. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000; 21:793-798.
15. (18)F-FDG-PET/CT in colorectal liver metastases - comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008; 35:1323-1329.
16. 18FDG -PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007; 34:1906-1914.
17. Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ. Comparison of multiphase CT, FDG-PET and infra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007; 14:818-826.
18. 18F] fluoro-2-deoxy- D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92:362-369.
19. Bellomi M, Rizzo S, Travaini LL, Bazzi L, Trifiro G, Zampino MG, et al. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer. Radiol Med (Torino) 2007; 112: 681-690.
20. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240:1027-1036.
21. Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem, et al. Clinical value of whole body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001; 27:175-179.
22. Rohren EM, Paulson EK, Hagge R, Wong TZ, Killius J, Clavien PA, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 2002; 27:550-555.
23. Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003; 44:240-243.
24. 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178:282-287.
25. Ruers TJ, Langenhoff BS, Neelman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20:388-395.
26. Lubezky N, Meteer U, Geva R, Nakache R, Shmueli E, Klausner JM, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. Gastrointest Surg 2007; 11:472-478.
27. Marom EM, Mc Adams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809.
28. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Man J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for pre-operative staging. Radiology 2005; 236:1011-1019.
29. Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007; 80:508-515.
30. Oto A, Tamm EP, Szklaruk J. Multidetector row CT of the liver. Radiol Clin North Am 2005; 43:827-848, vii.
31. Jones EC, Chezmar JL, Nelson RC, Bernardino ME. The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. Am J Roentgenol 1992; 158:535-539.
32. Khandani AH, Wahl RL. Applications of PET in liver imaging. Radiol Clin N Am 2005; 43:849-860, vii.
33. Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med 2005; 46:283-291.